Page 154 - Genentech News Today

“If I were to write the guidelines, I would recommend against using it. There is no benefit for this approach,” Tudor Jovin says.

/PRNewswire/ -- Lung cancer has emerged as one of the most commonly occurring ailments across the globe. This deadly disease has a high number of mortality...

Ocular Surgery News | The recent approval of pegcetacoplan for geographic atrophy, which may be followed shortly by avacincaptad pegol, is the first milestone answer to an unmet need, giving hope to patients who so far had no treatment options.It also paves the way for revolutionary changes in clinical practice, research, investment decisions and health care planning.

Marc Tessier-Lavigne has been vocal in defying his critics, even amid an investigation into image-manipulation allegations. Experts say the strategy may be risky.

Treatment with luspatercept vs. epoetin alfa nearly doubled the number of patients with lower-risk myelodysplastic syndrome who no longer required red blood cell transfusions for anemia, results of the phase 3 COMMANDS trial showed.The findings, scheduled for presentation at ASCO Annual Meeting, showed luspatercept (Reblozyl; Celgene, Bristol Myers Squibb) — an erythroid maturation agent

Basel, 26 May 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will be presenting new data on six approved and investigational medicines across ten cancer types...

NEW YORK and MAINZ, GERMANY, MAY 26, 2023 - Pfizer Inc. and BioNTech SE today announced they have reached an agreement with the European Commission to amend their existing contract... | May 26, 2023

Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with the European Commission NEW YORK and MAINZ, GERMANY, MAY 26, 2023 - Pfizer Inc. ... | May 26, 2023

Wabi Sabi Productions Inc. receives a “Telly Award” for its short documentary film entitled “Disabled Artist Showcase: Creating Our Spaces.” The film...

NIH, the world's largest biomedical research agency, was granted massive amounts of money to get to the bottom ...